Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.59 |
| ▸ | ATR | Q13535 | 1/20 | 0.58 |
| ▸ | SGK1 | O00141 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984228 | 0.90 | MTOR (0.64) | MTORPIK3CAPIK3R1SGK1 | |
| SCHEMBL3994797 | 0.89 | SGK1 (0.59) | MTORPIK3CAPIK3CGPIK3R1SGK1 | |
| SCHEMBL8189625 | 0.88 | SGK1 (0.58) | MTORPIK3CAPIK3CGPIK3R1SGK1 | |
| SCHEMBL4293191 | 0.85 | SGK1 (0.56) | MTORPIK3CAPIK3R1SGK1 | |
| SCHEMBL3992516 | 0.85 | SGK1 (0.56) | MTORPIK3CAPIK3R1SGK1 | |
| SCHEMBL3986299 | 0.85 | SGK1 (0.54) | MTORPIK3CAPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL3989155 | 0.85 | SGK1 (0.53) | MTORPIK3CAPIK3R1SGK1 | |
| SCHEMBL3986980 | 0.83 | SGK1 (0.56) | MTORPIK3CAPIK3R1SGK1 | |
| SCHEMBL3992288 | 0.83 | MTOR (0.56) | MTORPIK3CAPIK3CGPIK3R1SGK1 | |
| SCHEMBL3988805 | 0.82 | SMN1; SMN2 (0.62) | MTORPIK3CAPIK3CGPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.